RxDoctor Payments Data

Md Huq, MD

Internal Medicine · Ocala, FLNPI 1639183049

Payments from drug & device makers

$763in general payments, 2019–2025

Across 36 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$209
  • GSK$99
  • Novo Nordisk$92
  • Dexcom, Inc.$88
  • AstraZeneca$63
  • Novartis$61
  • plus $151 from 6 others

What the payments were for

  • Food & beverage$763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$763 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$340,448
Medicare patients
293
Services billed
3,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban148$156,567
FarxigaDapagliflozin Propanediol109$135,697
OzempicSemaglutide76$102,122
JardianceEmpagliflozin81$91,671
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$60,187
EntrestoSacubitril/Valsartan55$59,341
JanuviaSitagliptin Phosphate48$57,732
XareltoRivaroxaban28$46,441
MounjaroTirzepatide38$40,639
RybelsusSemaglutide25$36,399
Spiriva RespimatTiotropium Bromide28$19,067
MyrbetriqMirabegron20$18,165
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$16,152
Repatha PushtronexEvolocumab15$12,153
Breo ElliptaFluticasone/Vilanterol13$10,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$156,567148 claims
AstraZenecaFarxiga, Symbicort$63$140,030124 claims
Novo NordiskOzempic, Rybelsus$92$138,521101 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$35$126,890131 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix$99$79,25496 claims
NovartisEntresto$61$59,34155 claims
Johnson & JohnsonXarelto$13$46,44128 claims
Lilly USA, LLCMounjaro$46$40,63938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →